Intangible assets are one of the five recognized sources of an economic moat in Morningstar's framework — alongside cost advantage, switching costs, network effect, and efficient scale. The category covers brands, patents, trademarks, copyrights, regulatory approvals/licenses, and other legal or perceptual barriers that let a company either exclude competitors from a market or charge a premium customers willingly pay. The core tension is that an intangible asset is only a moat when it produces a measurable economic outcome — pricing power or customer captivity that shows up in sustained returns on invested capital (ROIC) above the cost of capital. A famous logo, a long patent list, or a high accounting "goodwill" line on the balance sheet are not, by themselves, evidence of a moat.

How it's formed

Intangible moats come in two economically distinct flavors:

• Legal exclusion (patents, regulatory licenses). A patent legally bars rivals from selling a specific invention for a fixed term (in the U.S., generally 20 years from filing). Regulatory approvals, FDA exclusivity periods, broadcast spectrum, and operating licenses work similarly — they cap the number of legitimate suppliers. The moat is contractual and finite; it has an expiry date.
• Perceptual pricing power (brand). A brand is a moat only when it raises a customer's willingness to pay or increases customer captivity — not merely when it's well-known. Morningstar's standard illustration: Sony is a household name, yet buyers rarely pay a premium for a Sony component over a comparable Samsung one, so the brand is not a moat there. Tiffany & Co. can charge thousands more for an equivalent diamond because of the brand and the blue box, so its brand is a moat. Awareness ≠ pricing power.

Note that accounting "intangible assets" and "goodwill" on the balance sheet are a poor proxy for an intangible moat: internally built brands (Coca-Cola, Nike) are largely not capitalized, while acquired goodwill can sit on the books of a company with no durable advantage at all.

How it's used in practice

Analysts test for an intangible moat by working backward from economics, not forward from reputation:

• Pricing-power test. Does the company sustain gross margins and price increases above peers without losing volume? Persistent premium pricing that competitors can't replicate is the signature of a brand moat (e.g., luxury, premium spirits, some consumer staples).
• ROIC durability. Morningstar's wide/narrow/none ratings rest on whether excess returns on capital are likely to persist ~10 (narrow) or ~20 (wide) years. An intangible asset earns a moat rating only if it underwrites that durability.
• Patent-portfolio depth, not single patents. A single patent is a shaky long-term moat because of expiry and litigation risk. A durable patent moat looks like a renewing pipeline and broad portfolio — the case made for diversified pharma/industrial libraries (e.g., Eli Lilly, Merck, 3M) rather than a one-drug biotech.
• Brand reinvestment cost. Watch advertising/marketing intensity. A brand that requires ever-rising ad spend just to hold share is weaker than one that compounds on word-of-mouth.

Adoption, debate & evidence

The five-source moat taxonomy originated at Morningstar (developed under research director Pat Dorsey, 2000–2011) and is now widely used by long-horizon equity investors; it underpins the VanEck Morningstar Wide Moat ETF (MOAT). VanEck's own moat education materials describe intangible assets as among the most prevalent moat sources in the wide-moat universe it tracks (note this is the index provider's characterization, not an independent finding).

On whether moats produce excess returns, the evidence is genuinely mixed and should not be overstated:

• Supportive: research cited by VanEck/Morningstar argues firms with durable advantages tend to deliver higher risk-adjusted total shareholder returns than standard asset-pricing models predict. Some academic work has tried to measure competitive advantage textually from 10-K filings and link it to subsequent returns — but such results are isolated, use proxies that are not "brand value," and should not be read as settled fact.
• Skeptical: multiple reviews note the empirical evidence on wide moats is mixed, and that high ROIC is a necessary but not sufficient condition for alpha. A moat can be real and the stock still a poor investment if it's overpriced — the moat is a quality signal, not a buy signal.

The hardest, best-measured evidence concerns the fragility of patent moats. The FDA's "Generic Competition and Drug Prices" analysis (drugs with initial generic entry 2015–2017) found generic price falls steepen sharply with competitor count: roughly 39% below the pre-entry brand price with one generic, ~54% with two, ~79% with four, and more than 95% with six or more (using average-manufacturer-price data; invoice-based figures are somewhat smaller). Beyond that FDA ladder, the precise pace of branded-revenue erosion is contested and source-dependent: industry briefings commonly cite first-year branded-revenue loss for small-molecule blockbusters facing multi-source generics in the rough range of 80–90%, with biologics facing biosimilars eroding more slowly — but these are estimates, not a single measured statistic, and vary widely by drug. More than $300 billion in branded pharma revenue is widely estimated to lose exclusivity between 2025 and 2030 (multiple analysts; ~one-sixth of industry revenue). Treat the magnitudes as orders of magnitude, but the direction is unambiguous: legal-exclusion moats end on a known schedule, often abruptly.

Strengths & limitations

Intangible moats can be the most powerful source, because brand pricing power can persist for decades with low reinvestment, and regulatory/patent exclusion can confer near-monopoly economics while it lasts. They work best where the asset is renewing (a brand continuously reinforced by use; a portfolio continuously refreshed by R&D) and where customers, not just regulators, value it.

They fail in three characteristic ways. First, the patent cliff — a finite legal asset expires and revenue collapses on a known date (the most measurable failure mode, above). Second, brand erosion — a brand that doesn't translate into pricing power (Sony case), or that decays through over-extension, scandal, or shifting taste; brand "value" can also vanish faster than its slow build suggests. Third, accounting illusion — confusing balance-sheet intangibles/goodwill with an economic moat.

The single most common misuse: equating brand recognition with a brand moat. The test is never "is it famous?" but "does it command a price premium or captivity that rivals cannot replicate, and does that show up in durable excess returns on capital?"

System relevance

This is a definition node within Fundamental Analysis → Business & Competitive Analysis → Economic Moats. It is the conceptual sibling of the other four moat-source nodes (cost advantage, switching costs, network effect, efficient scale) — for the overarching framework and how moat width (wide/narrow/none) and trend map to ROIC durability, see the parent Economic Moats node rather than duplicating it here.

Sources

• Morningstar / Pat Dorsey, The Little Book That Builds Wealth and Morningstar Economic Moat Rating methodology — five moat sources; Sony vs. Tiffany brand illustration.
• VanEck, "What Makes a Moat? Morningstar's Five Sources of Moat" (white paper, Jan 2025) and "An Investor's Guide to Intangible Assets" — intangibles as the leading moat source.
• VanEck / Morningstar materials on moats and risk-adjusted returns, plus academic 10-K-based competitive-advantage studies — mixed/contested evidence; not settled fact.
• U.S. FDA, "Generic Competition and Drug Prices" (drugs with initial generic entry 2015–2017; the verified ~39% / 54% / 79% / >95% price-reduction-by-competitor-count ladder). Note: an earlier draft attributed a "~21% of brand price at 12 months / 80-conversion" figure to FDA that could not be corroborated in the FDA source and has been removed.
• DrugPatentWatch / DeepCeutix / Evaluate / PharmaVoice industry briefings on the patent cliff (rough 80–90% first-year erosion for small molecules; ~$300B+ exclusivity loss 2025–2030; slower biologic/biosimilar erosion). Industry estimates — figures vary by source; treat as orders of magnitude, not measured statistics.
• Morgan Stanley Counterpoint Global, Measuring the Moat — analytical framework for assessing competitive advantage durability.